Covid19

No benefit of low dose apixaban following acute COVID-19 – News Medical

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

Read more at www.news-medical.net

Show More

Related Articles

Back to top button